IMA — ImageneBio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1835579 ·
Last close
$5.82
Market Cap
$65.64M
52W High
$6.99
52W Low
$3.94
ADV30
78,427
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -12,079,000 | -10,619,000 | 136,682,000 | 76,048,000 | 13,355,000 |
| Dec 2025 | 0 | — | -8,504,000 | -6,908,000 | 152,976,000 | 94,532,000 | 19,837,000 |
| Sep 2025 | 0 | — | -26,594,000 | -24,779,000 | 160,878,000 | 103,162,000 | 21,046,000 |
| Mar 2025 | 800,000 | — | -5,995,000 | -6,077,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,693,000
Investing CF
$-1,261,000
Financing CF
$6,906,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.46
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-230,053,000
Inventory
—
Receivables
$1,296,000
ST Investments
$40,817,000
EBIT TTM
$-43,276,000
Pretax Income TTM
$-40,019,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-54,038,248
Free Cash Flow
$-27,264,376
Enterprise Value
$-52,080,036
Total Cash
$117,208,000
Total Debt
$2,416,000
Shares Out
11,279,130
Trailing EPS
$-4.74
Book Value
$11.91
ROE
-86.2%
ROA
-45.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 800,000 | -48,451,000 | -45,349,000 | 152,976,000 | 19,837,000 | — | -47,844,000 |
| Dec 2024 | 3,500,000 | -37,000,000 | -36,568,000 | 15,922,000 | 176,487,000 | — | -21,319,000 |
| Dec 2023 | 7,962,000 | -21,925,000 | -21,148,000 | 31,245,000 | 157,353,000 | — | -18,233,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.98
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TCRX | TScan Therapeutics, Inc. | $65.35M | $1.07 | — |
| BSEM | BIOSTEM TECHNOLOGIES | $66.41M | $3.91 | — |
| ENTX | Entera Bio Ltd. | $59.56M | $1.21 | — |
| SGMO | SANGAMO THERAPEUTICS, INC | $76.68M | $0.19 | — |
| TIL | Instil Bio, Inc. | $55.07M | $8.12 | — |
News headlines (Yahoo Finance, 1h cache)
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
2026-05-07 20:05 · Yahoo
ImageneBio Announces $30 Million Private Placement
2026-04-13 11:00 · Yahoo
Image Resources NL (ASX:IMA) Is About To Turn The Corner
2026-04-01 20:11 · Yahoo
Imax announces $28M opening weekend for Amazon/MGM/s ‘Project Hail Mary’
2026-03-24 12:35 · Yahoo
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-03-17 20:30 · Yahoo
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
2026-03-10 12:00 · Yahoo
ImageneBio to Participate in Leerink Global Healthcare Conference
2026-02-26 13:00 · Yahoo
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
2026-02-10 12:00 · Yahoo
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap
2025-12-31 11:39 · Yahoo
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation
2025-11-15 13:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.